Rpg Life Sciences Ltd. (NSE: RPGLIFE, BSE: 532983) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹4,863 Cr, it ranks #849 by market cap among the 6,137 Indian listed companies on FinBizNet, and #26 of 86 in Medicinal Chemicals and Botanical Products. At ₹2,619.60 (as of 25 Oct 2026), the share price is 16.2% below its 52-week high of ₹3,127.80 and 51.2% above its 52-week low of ₹1,733.00. The share price is up 13.6% over one year and down 10.8% over three months.
| Current Price | ₹2,619.60 |
|---|---|
| Market Cap | ₹4,863 Cr |
| NSE Symbol | RPGLIFE |
| BSE Code | 532983 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 40.8 |
| Return on Equity | 20.28% |
| Return on Assets | 10.84% |
| 52-Week Range | ₹1,733.00 – ₹3,127.80 |
| 1-Year Price Change | +13.6% |
| 3-Month Price Change | -10.8% |
| Beta (1Y) | -0.02 |
| Dividend Yield | 0.84% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.rpglifesciences.com |
| Revenue | ₹196 Cr |
|---|---|
| Net Profit | ₹31 Cr |
| Net Margin | 15.7% |
| EPS (Basic) | ₹18.60 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
RPG Life Sciences Limited, an integrated pharmaceutical company, develops, manufactures, and markets branded formulations, generic, and synthetic active pharmaceutical ingredients (APIs) in India and internationally. The company offers synthetic APIs in various therapeutic categories, including immunosuppressants, anti-psychotic, anti-anginal, anthelmintics, anti-convulsant, anti-spasmodic, etc. It also provides generics for immunosuppressant therapy; and finished dosage formulations for various therapies, which include nephrology, rheumatology, oncology, gastroenterology, cardiology, orthopedics, nutritional, diabetology, respiratory, neuropsychiatry, urology, vitamins and minerals, gastrointestinal, pain management, anti-diabetic, gynecology and pediatrics, cardiovascular, pediatrics, neurology, anti-dengue, dermatology, etc. The company was formerly known as RPG Pharmaceuticals Limited and changed its name to RPG Life Sciences Limited in February 2008. RPG Life Sciences Limited was
1. Pharmaceuticals-This segment manufactures and markets branded formulations, generics, and active pharmaceutical ingredients. 2. Investment & Lending-0 3. Corporate-0
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Rpg Life Sciences Ltd. | ₹4,863 Cr | 40.8 | 20.28% | ₹196 Cr | +13.6% |
Listed by market capitalisation. Ratios are shown for context only.
Rpg Life Sciences Ltd. is trading at ₹2,619.60, with a market capitalisation of ₹4,863 Cr.
Rpg Life Sciences Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Rpg Life Sciences Ltd. has a P/E of 40.8 and a return on equity of 20.28%.
Rpg Life Sciences Ltd. is listed on the NSE under the symbol RPGLIFE and on the BSE under the scrip code 532983.
Rpg Life Sciences Ltd.'s share price is up 13.6% over one year and down 10.8% over three months. Its 52-week range is ₹1,733.00 to ₹3,127.80.
In Q1 FY27, Rpg Life Sciences Ltd. reported revenue of ₹196 Cr and net profit of ₹31 Cr, with basic EPS of ₹18.6 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.